--- title: "Vor Bio names Sandy Mahatme CFO and grants 13,882,750 inducement RSUs" url: "https://aibio.space/news/vor-bio-names-sandy-mahatme-cfo-grants-13-882-750-inducement-rsus/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-07-10" section: "Listings" tickers: "NASDAQ:VOR" source: "https://www.sec.gov/Archives/edgar/data/1817229/000119312525157638/d933755dex991.htm" summary: "Vor Bio appointed Sandy Mahatme as chief financial officer and chief business officer effective July 9, 2025, and granted him 13,882,750 restricted stock u" --- By the aibio.space news desk. Sources - [Vor Biopharma Inc. 8-K (2025-07-10)](https://www.sec.gov/Archives/edgar/data/1817229/000119312525157638/d933755dex991.htm) - [Vor Biopharma Inc. 10-K (2025-03-20): business](https://www.sec.gov/Archives/edgar/data/1817229/000095017025042623/vor-20241231.htm) [VOR](https://aibio.space/companies/vor-biopharma/) 2025-07-10 # Vor Bio names Sandy Mahatme CFO and grants 13,882,750 inducement RSUs Tickers [VOR](https://aibio.space/companies/vor-biopharma/) Vor Bio appointed Sandy Mahatme as chief financial officer and chief business officer effective July 9, 2025, and granted him 13,882,750 restricted stock units under Nasdaq's inducement rule. The release gives no share count or grant value to compare that award with. ## Key facts - **Company**: Vor Biopharma Inc. (NASDAQ: VOR) - **News type**: Listings - **Primary source**: [Vor Biopharma Inc. 8-K (2025-07-10)](https://www.sec.gov/Archives/edgar/data/1817229/000119312525157638/d933755dex991.htm) *The Capitol in autumn. CC0, via rawpixel. The picture shows the field, not the companies named.* Vor Bio, a clinical-stage biotechnology company in Cambridge, Massachusetts, listed on Nasdaq as VOR, appointed Sandy Mahatme as chief financial officer and chief business officer, effective July 9, 2025. The company announced the appointment in a press release dated July 10, 2025, which it filed with the SEC as Exhibit 99.1. The release ties the hire to advancing telitacicept through global Phase 3 development. ## The new chief financial officer The release says Mahatme has more than 30 years of executive experience in the biopharmaceutical industry. He most recently served as president, chief operating officer and chief financial officer of National Resilience, Inc., a biomanufacturing company he co-founded in 2020. The release says he raised over $2.5 billion in equity and non-dilutive capital there. Before that, he was executive vice president, chief financial officer and chief business officer at Sarepta Therapeutics, where the release says he led capital formation efforts exceeding $3.5 billion. It says he also built Sarepta's pipeline through licenses, collaborations and acquisitions. Earlier roles include senior vice president of corporate development and corporate treasurer, and senior vice president of tax, at Celgene Corporation, and senior positions at Pfizer, Inc. and Ernst & Young, LLP. He sits on the boards of CRISPR Therapeutics and Idorsia Pharmaceuticals, and holds Master of Laws degrees from Cornell Law School and New York University School of Law and is a member of the New York Bar. Chief executive Jean-Paul Kress said Mahatme's "financial acumen, operational discipline, and significant experience navigating strategic growth in both private and public biotech settings" will be instrumental as the company advances telitacicept through global Phase 3 development. The release does not say which of those raises were dilutive to shareholders, or what they cost the companies that made them. ## The inducement award On July 9, 2025, the board granted Mahatme 13,882,750 restricted stock units in connection with the start of his employment. The release says the award was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The award was made under the company's 2023 Inducement Plan. The units vest over four years. 25% of the shares vest on July 1, 2026, and the remaining 75% vest in equal quarterly installments over the following three years. Vesting depends on Mahatme staying employed with Vor Bio on each date. The release does not give Vor Bio's shares outstanding, the share price on the grant date or the value of the award, so readers cannot judge the size of the grant against the company's stock. It also gives no salary, bonus or other terms of his employment. ## The company's framing Mahatme is quoted as saying Vor Bio is well positioned, pointing to a late-stage asset that is already approved in China for several autoimmune indications and is in Phase 3 global development for generalized myasthenia gravis outside China. He also cites an experienced leadership team and a top-tier investor base. The release does not give any trial data, cash balance or financing plan to support that view. It describes the company as a clinical-stage biotechnology company focused on advancing telitacicept through Phase 3 development and commercialization. The release's forward-looking statements point readers to the risk factors in the company's annual and quarterly reports, without summarizing them. ## What the release leaves out The release names no bank, placement agent, financial advisor or counsel for the appointment or the award. It also does not name the officer who held the chief financial role before Mahatme, or say whether that person has left the company. The release gives no timetable for when the company expects to need new capital, and it does not say how the award compares with the company's cash. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story VOR Vor Biopharma Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/vor-bio-names-sandy-mahatme-cfo-grants-13-882-750-inducement-rsus/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Vor Bio names Sandy Mahatme CFO and grants 13,882,750 inducement RSUs", 2025-07-10, https://aibio.space/news/vor-bio-names-sandy-mahatme-cfo-grants-13-882-750-inducement-rsus/